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demonstrated reverse remodeling as defined by a 10% reduction in the LV end systolic
volume (ESV). Patients with 10% reduction in LV ESV had significantly less 1 year
mortality (0% vs. 20%, p0.036) (Figure) and had: less diabetes, lower baseline LVEF,
higher LV ESV and LV end systolic diameter (ESD)posterior wall thickness (PWT), and
worst pulmonary vein flow with decreased pulmonary vein S/D velocity (all p0.05), less
post TAVR aortic insufficiency (AI) (p0.059), at 6 months of follow-up patients with
reverse remodeling were more likely to have more improvement in LV ESV, EDV, LVEF
and LV ESD (all p0.05) (Table). In the binary logistic regression analysis significant
predictors of reverse remodeling was the severity of AI after the procedure (OR 9.5, 95%
CI 1.3-68, p0.025).
Conclusions: Reverse LV remodeling is noticeable in a significant proportion of patients
after TAVR. It is associated with significant reduction in 1 year mortality after TAVR.
Severity of AI after the TAVR is a significant predictor of LV reverse remodeling after
TAVR.
TCT-897
Variation in Use, Costs, and Hospital Profitability for Aortic Valve
Replacement Procedures: A Descriptive Analysis
Laura Okpala1, Randel Richner1, Mary Ann Clark1
1Neocure, Washington, DC
Background: As Medicare coverage policies around utilization of new aortic valve
technologies are beginning to include procedure utilization requirements for hospital
certification, it is increasingly important to know more about the geographic variation of
current aortic valve replacement (AVR) procedures. The purpose of this study is to
describe the variation in patterns of care and costs associated with AVR procedures in the
hospital inpatient setting from a Medicare perspective.
Methods: Medicare inpatient hospitalizations for aortic valve replacement (AVR)
procedures were identified using ICD-9-CM procedure codes found in the Medicare
Provider Analysis and Review (MEDPAR) 2010 database. Hospital volumes, charges,
costs, and reimbursements were summarized by hospital, Hospital Referral Region (HRR)
and Medicare region.
Results: We found a total of 48,449 inpatient AVR procedures completed across 1,147
Medicare participating hospitals in 2010. Total inpatient AVR procedure costs were $2.1
billion, with Medicare reimbursement totaling almost $2.4 billion. Per procedure, the
average hospital net Medicare margin was 10.3% or $5,927. The top 5 HRRs with the
highest volume of AVR procedures included Manhattan, NY, Los Angeles, CA,
Cleveland, OH, Boston, MA and Philadelphia, PA. Medicare Region 4 (Atlanta) and
Region 5 (Chicago) represented the highest regional volume of AVR procedures
capturing over 36% of market share with Region 8 (Denver) having the lowest AVR
procedure volume. Similarly, 36% of AVR procedures were performed at 9.4% of
hospitals.
Table 1- Top 5 Hospitals- Inpatient AVR Utilization and Costs
Hospital Name
Medicare
AVR
Procedure
Volume
Avg.
AVR
Hospital
Cost ($)
Avg. AVR
Hospital
Reimbursement
($)
Avg.
AVR
Hospital
Medicare
Net
Margin
($)
Avg.
AVR
Hospital
Medicare
Net
Margin
(%)
OH -
CLEVELAND -
CLEVELAND
CLINIC -
360180
928 $38,742 $51,093 $12,351 24.20%
NY - NEW
YORK - NEW
YORK-
PRESBYTERIAN
HOSPITAL -
330101
648 $51,437 $73,424 $21,986 29.90%
MN -
ROCHESTER -
MAYO CLINIC -
SAINT MARYS
HOSPITAL -
240010
503 $40,494 $50,629 $10,135 20.00%
NY - ROSLYN -
ST FRANCIS
HOSPITAL,
ROSLYN -
330182
413 $61,885 $50,735 -11150 -22.00%
MA - BOSTON -
BRIGHAM AND
WOMEN’S
HOSPTIAL -
220110
364 $55,486 $62,379 $6,893 11.10%
Conclusions: AVR procedures are seemingly concentrated in certain parts of the country
and at certain hospitals. As Medicare sets volume requirements to allow hospitals to
perform certain new AVR procedures, the implications of this variation warrant further
analysis.
TCT-898
Incidence and Impact of Acquired Thrombocytopenia on Bleeding Events and
Mortality after Transcatheter Aortic Valve Replacement (TAVR)
Philippe Genereux1, Susheel Kodali1, Martin Leon1, Philip Green1,
Benoit Daneault1, Jean-Michel Paradis1, Isaac George1, Ajay Kirtane1,
Rebecca Hahn1, Craig Smith1, Mathew Williams1
1Columbia University, New York, NY
Background: Transcatheter aortic valve replacement (TAVR) involves placement of a
stented valve across the native diseased aortic valve. Concern about platelets consumption
and acquired thrombocytopenia (AT) was raised in the early TAVR experience.
Methods: Between 2008 and 2011, 218 consecutive pts with severe aortic stenosis
underwent TAVR using the 23mm or 26mm Edwards SAPIEN valve. Platelet count was
evaluated the day prior and daily for 7 days after TAVR. AT was defined as a drop in
platelet count of50% of baseline. Thirty-day bleeding rate (life threatening or major by
VARC criteria) and 1-year mortality was evaluated.
Results: Post TAVR platelet count dropped by an average of 78	/44 x109/L.
Post-TAVR AT was present in 45/218 (20.6%) of subjects. At baseline, the AT group had
a higher frequency of female sex, prior coronary intervention, 23mm valve, higher mean
gradient and baseline platelet count. Post-op hemoglobin drop (3.3	/1.3 vs 2.3	/1.1,
p0.001) and at least 1 red blood cell transfusion (52.0% vs. 21.5%, p0.001) were more
frequent in AT group. Bleeding events occurred in 53.3% (24/45) in AT group vs 29.5%
(51/173) in no AT group [adjusted OR 3.3 95%CI [1.6-6.9], p0.002. One-year mortality
was higher in AT group [32.5% vs.18%, adjusted HR 3.2 (1.5-6.8) p0.002].
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Conclusions: AT is frequent after TAVR and associated with major bleeding events and
increased mortality. Larger studies are needed to confirm those results.
TCT-899
Risk of Respiratory Failure After Minimally Invasive Transapical Aortic
Valve Implantation
Martin Haensig1, David Holzhey1, Michael Borger1, Sven Lehmann1, Axel Linke1,
Joerg Seeburger1, Gerhard Schuler1, Friedrich Mohr1
1University of Leipzig - Heart Center, Leipzig, Germany
Background: Impaired respiratory function is believed to be a risk factor for transapical
aortic valve implantation (TA-AVI). The purpose of this study was to investigate the
incidence, predictors and impact of acute and chronic respiratory failure (ARF and CRF)
on procedural success and outcome.
Methods: 350 consecutive ‘high-risk’ patients, age 81.8 6.4 years, 66.3% female, were
included during a 4-year period. Preoperative estimated FEV1 was 91.9  33.6%. Mean
logistic EuroSCORE was 31.0 15.9% and mean STS-Score 12.0 7.7%. An uni- and
multivariate logistic regression analysis was performed.
Results: Regarding the postoperative respiratory outcome, ARF occurred in 14.9% and
interstitial lung disease (OR 23.40, p 0.01), transfusion 4 RBC units (OR 15.35,
p 0.001), brief reactive psychosis (OR 8.39, p 0.001), age  80 yrs (OR 3.66,
p  0.035) and vital capacity  60% (OR  3.23, p  0.025) were independent risk
factors for this event. Postoperative re-intubation was required in 17.1%. Vital capacity
60% (OR  2.94, p  0.046) and transfusion  4 RBC units (OR  16.00, p  0.001)
were independent risk factors for CRF. Short-term and long-term survival was explicitly
lower in the ARF, CRF and re-intubation groups (p  0.001 each).
Conclusions: Interstitial lung disease, age  80 yrs and vital capacity  60% are
preoperative risk factors for impaired respiratory outcome. Further studies will define if
the same risk factors can be expected using a transfemoral approach.
TCT-900
High-degree Atrioventricular Block and Need for Permanent Pacemaker
Implantation after Transcatheter and Surgical Aortic Valve Replacement.
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Chiara Bernelli1, Sandeep Basavarajaiah1, Tasuku Hasegawa1,
Francesco Maisano1, Antonio Colombo1
1San Raffaele Institute, Milan, Italy, 2Department of cardiology, Ain Shams
University, Cairo, Egypt, Cairo, Egypt
Background: To evaluate the incidence and predictors of high degree atrioventricular
block (HDAVB) and permanent pacemaker implantation (PPM) following surgical aortic
valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI).
Methods: We analyzed clinical, electrocardiographic, echocardiographic and peri-
procedural data from 336 patients (pts) without prior pacemaker who underwent TAVI
with either CoreValve (n130) or Edwards-Sapien (n206) prostheses between 2007
and 2011 and from 210 elderly pts (75 years) undergoing SAVR between 2005 and
2010 in our centre.
Results: Mean age was similar in TAVI:79.47.3 vs. SAVR:79.072.86 years
(p0.45). TAVI exhibited an higher risk profile (Log Euroscore 22.915.8% in TAVI vs.
13.111.8% in SAVR, p0.0001). HDAVB occurred in 10% SAVR vs. 13.9% TAVI
pts (p0.2) with an higher resolution in SAVR (90.5%) and 2 pts (0.95%) implanted
PPM. PPM implantation was higher in TAVI (n51, 15.2%, p0.001) mostly due to
HDAVB (86.3%) and was lower in Edwards (6.7%) vs. CoreValve (23.1%) group
(p0.001). The main causes of PPM implantation were: 3rd AVB (40pts, 78.5%), 2nd
AVB Mobitz 2 (2pts, 4%), symptomatic LBBB and 1st AVB (2pts, 4%), atrial fibrillation
with a ventricular rate40/min (3pts, 6%), QRS widening (1pt, 1.9%), LBBB with sinus
bradycardia (2pts, 4%) and brady-tachy syndrome (1pt, 1.9%). The median time from
TAVI to PPM was 2 days (IQR0-12) and from SAVR was 13.5 days (IQR12-15). On
multivariable analysis, the predictors of HDAVB were pre-existing RBBB (OR:5.1 95%
CI 1.9-16.5; p0.005) and LAH (OR:3.9 95% CI 1.3-11.1, p0.011) in SAVR, whereas
ejection fraction below 35% (p0.052), CoreValve prosthesis (p0.001), post-dilatation
(p0.001) and RBBB at baseline (p0.001) predicted HDAVB in TAVI. On only
univariate analysis, the depth of valve implantation (p0.001) and ratio between valve
and annulus size (p0.001) predicted HDAVB after TAVI.
Conclusions: The need for PPM following TAVI was higher than SAVR (13.1 vs.
0.95%). Pre-existing RBBB and LAH were risk factors for HDAVB after SAVR. The
predictive factors for complete AVB and PPM in TAVI patients were pre-existing RBBB,
lower ejection fraction, CoreValve prosthesis and valve postdilatation.
TCT-901
Improved Mitral Valve Performance After Transapical Aortic Valve
Implantation
Martin Haensig1, David Holzhey1, Michael Borger1, Hendrik Treede2, Axel Linke1,
Joerg Seeburger1, Gerhard Schuler1, Friedrich Mohr1
1University of Leipzig - Heart Center, Leipzig, Germany, 2University of Hamburg -
Heart Center, Hamburg, Germany
Background: Concomitant mitral regurgitation (MR) is frequently present prior to
transapical aortic valve implantation (TA-AVI). The aim was to study the impact of MR
on outcome and the effect of TA-AVI on MR using the Edwards SAPIENTM prosthesis.
Methods: A total of 439 patients, age 81.5  6.4 years, 64.0% female, unterwent
TA-AVI between Feb/2006 and Aug/2011. Mean logistic EuroSCORE was 29.7 
15.7% and mean STS-Score 11.4%  7.6%. Outcome was assessed in patients with
absent (9.8%),  mild (58.5%), moderate (29.7%) and severe (2.0%) MR by pre- and
postoperative echocardiography.
Results: Patients with moderate/severe MR versus  mild MR had an increased
in-hospital mortality (HR 2.69, 95% CI 1.43-5.06, p0.002), but a comparable 4-year
survival (HR  0.73, 95% CI 0.27-1.93, p  0.520). During postoperative echocardio-
graphic examination, there was an overall improvement in mitral incompetence (absent in
23.7%, mild in 58.6%, moderate in 17.7%, and severe in none). Independent multivariate
predictor’s of improved MR were a maximum trans-aortic gradient  50 mmHg (OR 
14.35, p  0.02), preoperative vena contracta width of the mitral valve  5.0 mm (OR 
8.93, p 0.004), left-ventricular posterior wall dimension  1.6 cm (OR  7.19, p 
0.001) and LVEF  60% (OR  4.92, p  0.007).
Conclusions: Moderate/severe MR prior to TA-AVI is associated with an increased
early, but a comparable late mortality. We observed an overall improved mitral valve
performance possibly by reducing closure forces acting on the mitral valve.
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Report from the Swedish TAVI register: Comparison of two valve types.
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Johan Nilsson6, Andreas Ruck7, Leszek Zagozdzon8
1Inst of Clin Sciences, Lund, Sweden, 2Linkoping University, Linkoping, Sweden,
3Uppsala Universitet, Uppsala, Sweden, 4Sahlgrenska University Hospital,
gothenburg, Sweden, 5Uppsala Clinical Research Center, Uppsala, Sweden, 6Umea˚
University, Umea˚, Sweden, 7Karolinska University Hospital, Stockholm, Sweden,
8Orebro University, Orebro, Sweden
Background: Registry data and recent a randomized trail have established the safety and
efficacy of TAVR in high risk operable and non-operable patients. Due to differences
between the two common valve types procedural results and outcome may differ. The
web-based on-line Swedish TAVI register have since the beginning 2008 captured all
implant procedures, 1 month and 1 year FU as well as it tracks mortality in 100% of
patients.
Methods: TAVI-procedures were only performed in the seven university hospital with
cardiac surgical backup. Three hospitals used the CoreValve and four the Edwards Sapien
device, none used both. Mortality tracking was performed via the national population
registry.
Results: From 2008-2010; 568 TAVI procedures were performed. The use of the two
devices was similar until 2011 with an increase in CoreValve procedures 122 vs. 87
Sapien. Approximately an equal number of men and women have been treated with a
mean age of 82. An increase in transfemoral procedures compared to other access routes
is observed. In 2011 the logistic Euroscore was higher for the CoreValve (27.5) compared
to the Sapien (25.0). Procedural results are presented in table 1.
Conclusions: From 2008 till 2011 the number of TAVI procedures shows a moderate
increase. Logistic Euroscore remains unchanged. Stroke numbers are low and have
decreased from 3 to 1.5 %. The 30 days and 1 year all-cause mortality rate is 6.4% and
14%. Besides the higher number of pacemaker implants in the CoreValve group no major
differences were seen between the two devices. The final analysis of the data will be
presented at the meeting.
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